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ABSTRACT  
Rationale: Airway remodeling, a characteristic feature of asthma, begins in early life. Recurrent 
human rhinovirus (HRV) infections are a potential inciting stimulus for remodeling. One 
component of airway remodeling is an increase in airway smooth muscle cell mass with a greater 
proximity of the airway smooth muscle cells (ASMC) to the airway epithelium. We asked 
whether human bronchial epithelial cells infected with HRV produced mediators that are 
chemotactic for ASMC.  
Methods: ASMC migration was investigated using the modified Boyden Chamber and the 
xCELLigence Real-Time Cell Analyzer. Multiplex bead analysis was used to measure HRV-
induced epithelial chemokine release. The chemotactic effects of CCL5, CXCL8 and CXCL10 
were also examined.  
Results: Supernatants from HRV-infected epithelial cells caused ASMC chemotaxis. Pre-
treatment of ASMC with pertussis toxin abrogated chemotaxis, as did treatment with formoterol, 
forskolin, or 8-bromo-cAMP. CCL5, CXCL8, and CXCL10 were most up-regulated chemokines 
produced by HRV-infected airway epithelial cells. When recombinant CCL5, CXCL8 and 
CXCL10 were used at levels found in epithelial supernatants they induced ASMC chemotaxis 
similar to that seen with epithelial cell supernatants. When examined individually, CCL5 was the 
most effective chemokine in causing ASMC migration and treatment of supernatant from HRV-
infected epithelial cells with anti-CCL5 antibodies significantly attenuated ASMC migration.   
Conclusion: These findings suggest that HRV-induced CCL5 can induce ASMC chemotaxis, 
and thus may contribute to the pathogenesis of airway remodeling in asthmatic patients. 
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INTRODUCTION 
 The airways of patients with asthma typically display a number of structural changes, 
including goblet cell metaplasia and excessive mucus production, thickening of the lamina 
reticularis, angiogenesis, and increased smooth muscle mass with a reduced distance between 
muscle cells and the airway epithelium as asthma severity increases (1, 2).  These changes, 
collectively termed airway remodeling, lead to a thickening of the airway wall. This has been 
suggested to contribute to airways hyperresponsiveness, in part by induction of increased airway 
narrowing for a given degree of smooth muscle shortening (3, 4). 
 In most patients, asthma initially manifests in childhood (5). It is therefore noteworthy that, 
while it was traditionally believed that airway remodeling occurred after years of chronic 
inflammation, a number of bronchial biopsy studies have now established that several major 
components of airway remodeling, including increased smooth muscle mass and thickening of 
the lamina reticularis, are already present in pre-school children, often before the clinical 
diagnosis of asthma has been made (6-8). Interestingly, signs of airway remodeling are not 
detected in infants with  wheezing illnesses (9), implying that exposure to some inciting stimuli 
in early childhood induces remodeling. 
 It is now well established that children who experience human rhinovirus (HRV)-induced 
wheezing illnesses in early life are at increased risk of subsequently developing asthma (10, 11), 
particularly if they are also sensitized to inhaled allergens (12). Pre-school age children have 
been shown to experience approximately six HRV infections each year (13), and serial HRV 
infections can cause recurrent wheezing episodes (14). Given the concomitant time frame of 
recurrent HRV-induced wheezing episodes and the development of airway remodeling, it is 
feasible that HRV infections could contribute to the initiation and progression of airway 
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remodeling in asthma. In the current studies we tested the hypothesis that HRV infection of 
airway epithelial cells induces release of chemotactic agents that could cause directional 
migration of airway smooth muscle cells (ASMC) towards the epithelium to contribute to the 
process of remodeling. 
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METHODS 
Details regarding all methods are provided in the Online Data Supplement. 
Cell Cultures: Primary human bronchial epithelial (HBE) cells were obtained via protease 
digestion of non-transplanted normal human bronchi as described (15), and grown in bronchial 
epithelial growth medium (BEGM). For these studies, cells were derived from 6 lung donors (5 
male; age range 13-63 years). All 6 donors died from  non-respiratory causes and none of them 
had any underlying lung disease. Human airway smooth muscle cells (ASMC) were obtained by 
micro-dissection and protease digestion and cultured in DMEM containing 10% FBS and 
antibiotics as described (16).   A total of 10 individual ASMC donors were used (8 male; age 
range 13-63 years). Protocols for obtaining cells were approved by the University of Calgary 
Conjoint Health Ethics Board.   
 
HRV Infection: HRV type 16 (HRV-16) was propagated in WI-38 cells and purified as 
described (17). Viral titers were determined as described (17). HBE cells were exposed to control 
medium or to 105.5 50% tissue culture infective dose (TCID50) U/ml (multiplicity of infection 
~1.0) of HRV-16 for 24 h at 34°C with 5% CO2. Epithelial cell supernatants from 6 individual 
donors were pooled for each experimental condition to generate stocks of conditioned medium 
(CM) and HRV-conditioned medium (HRV CM) for migration experiments. 
 
Migration Assay: ASMC migration was performed in both a AP48 modified Boyden chamber 
and the xCELLigence Real-Time Cell Analyzer system. ASMC were added to top wells of the 
AP48 chamber (40,000 cells/well) or the RTCA system (80,000 cells/well), while 
chemoattractants were added to the bottom chambers. Platelet-derived growth factor-AB (PDGF-
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AB) was used as a positive control stimulus for ASMC migration. Plates were incubated (4 h) at 
37°C and 5% CO2. Impedance data for the RTCA system were normalized at the earliest time 
point to control for differences in well loading and cell settling. Migration experiments used 
ASMC from the indicated number of individual tissue donors in each experiment (i.e. n = 
number of ASMC donors).  
 
64-chemokine Multiplex assay: Pooled CM or HRV-CM were used in a 64-chemokine 
multiplex protein assay performed by Eve Technologies (Calgary, AB, Canada). 
 
Flow Cytometry Analysis: ASMC were suspended using a non-enzymatic cell dissociation 
buffer. Fluorescently labeled antibody(s) was then added and the cells were allowed to incubate 
in the dark at 4°C for 2 h with rocking. Cells were fixed and stored at 4°C until analyzed by flow 
cytometry. 
 
ELISA assay for CXCL8: CXCL8 was assayed as previously described (18). 
 
Neutralizing antibody treatment of conditioned medium: Neutralizing monoclonal antibody 
to CXCL5, or appropriate isotype control, were added to HRV-CM and incubated at room 
temperature (2 hours) prior to use as chemoattractants for ASMCs. 
 
Cell viability: Cell viability following experimental interventions, was assessed using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. 
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Statistical Analysis: Data are presented as means ± SEM. Statistical analysis was performed by 
using ANOVA, and the Newman Keuls multiple comparison post hoc test. P values of less than 
0.05 were regarded as statistically significant. Statistical analysis was performed with GraphPad 
Prism 6 software.  
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RESULTS 
ASMC migrate to conditioned medium from HRV infected HBE cells 
Because the xCELLigence system provides real-time data, we used this apparatus to establish 
that ASMC migration started to plateau by 4 h (Figure E1 in the Online Supplement). Therefore, 
we used 4 h as the outcome time point for all subsequent experiments. 
Conditioned medium from HBE cells treated with medium control (CM) or HRV-16 (HRV-CM) 
for 24 hours were used as chemoattractants in both the Boyden Chamber and the xCELLigence 
system. CM was able to drive a migratory response that was higher than the medium alone; 
however the HRV-CM condition was able to drive significantly higher migration in both the 
Boyden chamber (Figure 1A) and the xCELLigence system (Figure 1B). HRV virion alone, at 
levels used to stimulate HBE cells, did not induce any migration of ASMC (Figure 1B). We next 
examined whether ASMC migration was directional or random by abolishing the chemotactic 
gradient in the xCELLigence system by adding the chemoattractant to both the top and bottom 
wells (Figure 1C).  While CM and HRV-CM were able to drive ASMC migration normally, 
migration to both stimuli was significantly attenuated (p<0.001) when there was no gradient 
present. Given the concordance in data from the modified Boyden chamber and the 
xCELLigence system, we used the xCELLigence system for all subsequent migration 
experiments.  
 
Migration to HRV-CM is mediated by molecules less than 30 kDa and chemoattractant 
production depends upon viral replication 
To gain insight into the molecule(s) responsible for ASMC migration to HRV-CM, centrifugal 
filtration devices were used to remove all materials >30 kDa (including HRV virions) from the 
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HBE cell supernatants. We validated that filtration did not retain low molecular weight 
molecules by demonstrating minimal loss of CXCL8 levels in the filtrate (Figure E2). Filtration 
did not alter the ability of HRV-CM to drive ASMC migration but significantly attenuated the 
ability of CM alone to drive ASMC migration (Figure 2A). To study the time course of 
chemoattractant generation from HBE cells, we collected conditioned medium at 3, 9, 15, and 
24h post HRV treatment. The chemotactic ability of HBE-CM for ASMC increased with time 
following HRV infection (Figure 2B). To determine if this increase was dependent upon the 
replication of HRV, cells were exposed to either intact HRV, capable of replication or to UV-
light treated, replication deficient HRV. Medium from cells  exposed to  replication competent 
virus generated a chemotactic response as  described, whereas  medium from cells exposed to  
replication deficient HRV did not induce significant ASMC chemotaxis (Figure 2C), confirming 
that viral replication within HBE cells is necessary to promote chemoattractant release. 
 
 Exposure to pertussis toxin inhibits ASMC migration to HRV-CM 
 A number of  low-molecular weight  chemoattractants, including chemokines, exert their effects 
via G-protein coupled receptors (GPCRs) which are often linked to the G-protein, Gαi (19).  We 
therefore studied whether the chemoattractant(s) contained in HRV-CM act through a Gαi-
coupled GPCR by exposing ASMC to pertussis toxin (PTX), which ADP-ribosylates and 
inactivates Gαi, prior to performing migration assays. There was no deleterious effect of PTX on 
ASMC viability (data not shown).  As  anticipated, PTX did not attenuate migration to PDGF-
AB, which functions via a receptor tyrosine kinase. In contrast, PTX significantly reduced 
ASMC migration to HRV-CM (Figure 3). 
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ASMC migration is sensitive to intracellular cAMP  
Given that Gαi-coupled GPCR can lower intracellular cAMP levels, we next examined the 
effects of elevating intracellular cAMP levels on ASMC migration. Activation of its Gαs-coupled 
GPCR by the β2-adrenergic agonist formoterol completely abolished migration to both CM and 
HRV-CM (Figure 4A). Similarly, direct activation of adenylyl cyclase in ASMC using the 
forskolin analogue NKH-477, or pretreatment with the cell-permeable cAMP analogue, 8-
bromoadenosine 3′, 5′-cyclic monophosphate (8-Br-cAMP), 15 min prior to use in the migration 
assay also both abrogated the migratory capacity of the ASMC (Figure 4B & 4C). Given that 
migration to HRV-CM and the receptor tyrosine kinase linked positive control, PDGF-AB, were 
both inhibited by agents that elevate intracellular cAMP, this suggests that this is a broad ranging 
regulatory pathway and not simply a competitor to Gαi-coupled GPCR-mediated reduction in 
intracellular cAMP. 
 
Identification of chemokines that facilitate HRV-induced ASMC migration 
To identify potential chemoattractants that may contribute to ASMC migration in response to 
HRV-CM, we performed a multiplex assay for 64 analytes (Luminex, Toronto, ON, Canada) on 
media obtained from a pool of 6 HBE cell donors exposed either to medium alone or to HRV. 
The 4 most highly up-regulated chemokines are shown in Figure 5.  
 
Flow cytometry data indicate the presence of several chemokine receptors 
Flow cytometry was performed to examine the expression of potential cell surface receptors for 
the chemokines identified above at the protein level.  These experiments used ASMC obtained 
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from 5 donors. A representative series of histograms showing surface expression of CXCR1, 
CXCR2, CXCR3, CCR1, CCR3 and CCR5 on ASMC from a single individual is shown (Figure 
6A). Mean percentage of cells expressing each receptor using cells from all 5 donors is shown in 
Figure 6B. 
 
HRV-induced ASMC migration is mediated, at least in part, via the chemokine CCL5 
To determine the potential of CCL5, CXCL8, and CXCL10 to induce ASMC migration using 
concentrations similar to those found in HRV-CM, we initially used the recombinant chemokines 
in concentrations of 500 pg/mL, 5000 pg/mL and 10000 pg/mL, alone and in combination.  The 
combination of the three chemokines induced ASMC migration that was significantly greater 
that that seem with CM and that was comparable to that observed for HRV-CM (Figure 7A). 
When examined individually, CXCL10 caused no significant migration, despite the high 
expression of CXCR3 on ASMC cells. Moreover, CXCL8 alone induced only a modest 
chemotactic response, presumably mediated via interactions with CXCR1.  By contrast, CCL5 
alone induced migration similar to that seen with HRV-CM, suggesting that CCL5 is the major 
chemoattractant for ASMC in HRV-CM. To further evaluate the role CCL5 in the ASMC 
migratory response, we incubated HRV-CM with a neutralizing antibody to CCL5 or with an 
isotype control. While the isotype control did not alter ASMC migration, the antibody to CCL5 
significantly abrogated ASMC migration to HRV-CM (Figure 7B).  
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DISCUSSION 
 Pre-school children who experience recurrent HRV-induced wheezing illnesses are not only 
at increased risk of subsequently developing asthma (10, 11), but already shows signs of airway 
remodeling, including increased airway smooth muscle mass (8). The relative contribution of 
hyperplasia versus hypertrophy to the increased smooth muscle mass in asthma is still somewhat 
controversial (20, 21), and may vary depending on the size of airways examined (22). The 
observation that airway smooth muscle cells are found closer to the epithelium in asthma implies 
that ASMC migration also occurs in asthma (2). Indeed, a number of studies have indicated that 
ASMC are capable of migrating to a variety of growth factors, including PDGF (23), as well as 
to selected chemokines (24-27). In this study, we show that human airway epithelial cells 
infected with HRV release chemotactic agents that can cause directed migration of ASMC 
towards the epithelial layer. The production of these chemoattactants depends upon viral 
replication within HBE cells, as conditioned medium from HBE cells exposed to UV-treated, 
replication deficient HRV did not induce significant ASMC migration.  
 To gain insights into the nature of the chemoattractants in HRV-CM we first demonstrated 
that chemotactic activity was retained in the filtrate after passage through a 30,000 Dalton filter, 
indicating that chemotactic agents were of relatively low molecular weight.  The observation that 
treatment of ASMC with pertussis toxin abrogated ASMC migration to HRV-CM indicated that 
chemoattractant agents in HRV-CM act via interactions with Gαi-coupled GPCR(s). Although a 
number of mediators satisfy these characteristics, the prior evidence for a role of chemokines in 
inducing ASMC migration in other systems (24-27) led us to perform multiplex analysis of 
chemokines in supernatants from epithelial cells exposed to medium or HRV. Induction of 
CCL5, CXCL8, and CXCL10 identified these chemokines as potential candidates to cause 
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ASMC chemotaxis, analysis, and this paradigm was further supported by detection of low level 
expression of receptors for each chemokine on ASMC by flow cytometry. Subsequent functional 
studies revealed that while CXCL10 was ineffective as a chemotactic agent for ASMC, despite 
the expression of the CXCR3 receptor on significant percentage of ASMC.  Although this seems 
paradoxical, these observations are consistent with those reported by Saunders et al (28). 
Presumably the inability of CXCL10 to function as a chemoattractant for ASMC relates to a lack 
of signaling downstream of the receptor.  This is quite distinct from our prior data showing that 
generation of this chemokine from HRV-infected HBE cells plays an important role in causing 
chemotaxis of fibroblasts (29). We also found that CXCL8 caused only modest ASMC 
migration, and that CCL5 was the most effective chemoattractant for ASMC. We confirmed that 
CCL5 was a major contributor to the chemotactic activity of HRV-CM for ASMC by 
demonstrating that incubation of HRV-CM with a specific blocking antibody to CCL5 largely 
abolished ASMC chemotaxis. Taken together our data are consistent with earlier reports that 
CCL5 derived from TNFα-stimulated epithelial cells was chemotactic for ASMC (30), and that 
CXCL8 can also stimulate ASMC migration (25, 30). 
 We also demonstrated in this study that elevation of cAMP in ASMC inhibits migration of 
these cells to a variety of stimuli, including HRV-CM and PDGF.  This was the case whether 
cAMP was induced via activation of the β2-adrenergic receptor, via direct activation of adenylyl 
cyclase, or via use of a cell permeable cAMP analogue. This data are consistent with an earlier 
report of a modulatory role of cAMP in regulating ASMC migration (31), but differ somewhat in 
that we found all mechanisms of cAMP elevation to be equally effective while Goncharova and 
colleagues found that inhibition of migration varied depending on the means of elevating cAMP 
(31). Our observation that a β2-adrenergic receptor agonist inhibits ASMC migration to a variety 
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of stimuli raises the possibility that the use of β2-adrenergic receptor agonists may help to 
attenuate some aspects of remodeling in asthma.  This would be consistent with a recent study 
showing that combination therapy with an inhaled corticosteroid and long-acting β2-adrenergic 
receptor agonist, but not an inhaled corticosteroid alone, inhibited antigen induced alterations in 
airway smooth muscle and myofibroblast numbers in asthmatic subjects (32). 
  Our study has several  limitations. We used cells from adolescent and adult donors, and 
future studies  will need to examine whether epithelial cells from  young children will show 
similar chemotactic  responses to HRV infection. In addition, both epithelial cells and ASMC 
used  in the current study were procured from healthy, non-asthmatic donors, in whom airway 
remodeling  is unlikely to have been  present. However,  even in the airways of normal subjects  
infected with  HRV , there is likely to be some effect and alteration in ASMC numbers and this 
may be what is reflected in our current model in the setting of low chemokine receptor 
expression on ASMC.  We speculate that the chemotactic responses  demonstrated in our present 
study, would be exaggerated if cells from asthmatic donors were used. Further studies will need  
to determine whether epithelial cells from subjects with asthma   generate higher  levels of 
chemokines   following HRV infection, and if so, whether ASMC from these asthmatic subjects  
show a greater chemotactic response to these   chemotactic cytokines. In that context, given the 
modest level of expression of receptors for CCL5 on our normal cells, it is of interest that ASMC 
from asthmatic subjects show increased expression of the CCR3 chemokine receptor (24), for 
which CCL5 is a known ligand. This would be expected to result in an increased number of 
ASMC cells from asthmatic subjects migrating to this chemokine. 
 In summary, we show that HRV infected epithelial cells release chemoattractants that can 
stimulate directed migration of ASMC.  CCL5 is the dominant chemoattractant present in HRV-
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CM, although CXCL8 may also contribute.  These data, together with earlier reports that HRV 
infected epithelial cells show expression of genes related to airway remodeling (33), and release 
a number of growth factors and matrix proteins linked to airway remodeling (34-36),  further 
support the concept that recurrent HRV infections may contribute to the initiation and 
progression of airway remodeling in asthma. Future studies will need to determine if the current 
observations are relevant to cells obtained from asthmatic subjects (both children and adults), 
while clinical studies of either naturally-acquired or experimental HRV infections will confirm 
whether these observations occur in vivo. 
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Figure Legends 
Figure 1: Conditioned Medium from HRV infected HBE cells (HRV-CM) drives ASMC 
chemotaxis. ASMC migration was assessed to conditioned medium from cells exposed to 
medium only (CM) or HRV-CM. A) Data using the modified Boyden chamber (n=4). B) Data 
using the xCELLigence system (n=3). Platelet derived growth factor-AB (PDGF-AB, 300 
ng/mL) was used as a positive control. C) Migration is abrogated when the chemotactic gradient 
is abolished (n=3).  Asterisk indicates p<0.05 for comparisons shown. 
 
Figure 2: HRV-induced induction of chemoattractants from HBE cells depends upon viral 
replication and chemoattractants are less than 30 kDa. A) HRV-CM and CM were passed 
over a 30 kDa filter and migration to the filtrates (white bars) were compared to those of 
unfiltered conditioned medium (grey bars), (n=3); B) HRV-CM was harvested at multiple time 
points (3, 9, 15, 24h) after HRV infection and used in chemotaxis assays (n=4); C) Conditioned 
medium from UV-inactivated HRV-16 treated epithelial cells (UV-HRV-CM) is ineffective as a 
chomattractant for ASMC (n=3). Asterisk indicates p<0.05 for comparisons shown. 
 
Figure 3: Treatment of ASMC with pertussis toxin (PTX) inhibits their migration to HRV-
CM but not to PDGF. Data are from 3 experiments. Asterisk indicates p<0.05 for comparison 
shown. 
 
Figure 4: Agents that elevate intracellular cAMP in ASMC inhibit migration to both HRV-
CM and PDGF. Migration of ASMC in response to PDGF-AB, CM, or HRV-CM was assessed 
in the xCELLigence system following pre-treatment (15 min) with: A) Formoterol (n=3); B) 
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NKH-477 (n=6); C) 8-Br-cAMP (n=3) or appropriate vehicle control for each agent. Asterisk 
indicates p<0.05 for comparisons shown. 
 
Figure 5: Identification of CCL5, CXCL8 and CXCL10 as possible chemotactic mediators 
of ASMC.  Levels of the 4 chemokines most strongly induced in response to HRV infection as 
assessed using a multiplex assay of combined supernatant from six HBE donors. Values are 
shown for cells exposed to medium alone, intact HRV-16 and UV-treated (replication deficient) 
HRV-15. 
 
Figure 6: Flow cytometry analysis of ASMC donor cells indicates the presence of several 
different chemokine receptors on ASMC membrane surfaces. A) Histograms showing 
expression of chemokine receptors relative to appropriate isotype control antibodies on ASMC 
from an individual donor. B) Mean ± SEM percentage of ASMC cells from 5 donors expressing 
each chemokine receptor. 
 
Figure 7: CCL5 is the major chemoattractant for ASMC in HRV-CM. A) Migration of 
ASMC was assessed to CXCL10 (10,000 pg/mL), CXCL8 (5,000 pg/mL), CCL5 (500 pg/mL), 
CM, or HRV-CM (n=3); B) ASMC migration was significantly inhibited after 1 h pre-treatment 
of HRV-CM with anti-CCL5 but not with isotype control (n=3). Asterisk indicates p<0.05 for 
comparisons shown. 
 
 
 










